Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.
Li S, Bao J, Li X, Yang Q, Xu J, Chen S, Feng G, Gao C, Feng L, Lu B, Miao M, Ni X, Wang G, Yang L, Zhu L. Li S, et al. Among authors: zhu l. EClinicalMedicine. 2023 Nov 20;66:102314. doi: 10.1016/j.eclinm.2023.102314. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38024480 Free PMC article.
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.
Wu JW, Zhou CF, Han ZX, Zhang H, Yan J, Chen J, Wang CB, Qin ZQ, Mao Y, Tang XY, Zhu LJ, Wei XW, Cui DH, Yang XL, Shi M, Zhao LQ, Jiang JL, Zhu WY, Wang HM, Wang C, Zhu LJ, Zhang J. Wu JW, et al. Signal Transduct Target Ther. 2024 Dec 9;9(1):344. doi: 10.1038/s41392-024-02051-4. Signal Transduct Target Ther. 2024. PMID: 39648217 Free PMC article. Clinical Trial.
Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial.
Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, Bi F, Zhu L, Guo Z, Yan J, Hu B, Tao M, Yang S, Zhang S, Wen L, Xu R. Wang F, et al. Among authors: zhu l. Chin J Cancer Res. 2021 Aug 31;33(4):490-499. doi: 10.21147/j.issn.1000-9604.2021.04.06. Chin J Cancer Res. 2021. PMID: 34584374 Free PMC article.
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.
Li J, Wang Z, Zhong H, He Y, Zhang C, Niu Z, Yang S, Zhang T, Zhu L, Shu Y, Gao Y, Peng J, Song Y, Li J, Yuan Y, Zhang H, Yu G, Hua Y, Xiao J, Fu J, Zheng Y, Xue H, Luo X, Shi M, Su W, Qin S. Li J, et al. Among authors: zhu l. Oncologist. 2024 Aug 5;29(8):e1012-e1019. doi: 10.1093/oncolo/oyae073. Oncologist. 2024. PMID: 38642091 Free PMC article. Clinical Trial.
29,813 results
You have reached the last available page of results. Please see the User Guide for more information.